The popular pressurized metered dose inhaler (pMDI), especially for asthma treatment, has undergone various changes in terms of propellant use and valve design. Most significant are the choice of hydrofluoroalkane-134a (HFA-134a) as a new propellant (rather than chlorofluorocarbon, CFC), a smaller exit nozzle diameter and attachment of a spacer in order to reduce ultimately droplet size and spray inhalation speed, both contributing to higher deposition efficiencies and hence better asthma therapy. Although asthma medicine is rather inexpensive, the specter of systemic side effects triggered by inefficient pMDI performance and the increasing use of such devices as well as new targeted drug-aerosol delivery for various lung and other diseases make detailed performance analyses imperative. For the first time, experimentally validated computational fluid-particle dynamics technique has been applied to simulate airflow, droplet spray transport and aerosol deposition in a pMDI attached to a human upper airway model, considering different device propellants, nozzle diameters, and spacer use. The results indicate that the use of HFA (replacing CFC), smaller valve orifices (0.25 mm instead of 0.5 mm) and spacers (ID ‫؍‬ 4.2 cm) leads to best performance mainly because of smaller droplets generated, which penetrate more readily into the bronchial airways. Experimentally validated computer simulations predict that 46.6% of the inhaled droplets may reach the lung for an HFA-pMDI and 23.2% for a CFC-pMDI, both with a nozzle-exit diameter of 0.25 mm. Commonly used inhalers are nondirectional, and at best only regional drug-aerosol deposition can be achieved. However, when inhaling expensive and aggressive medicine, or critical lung areas have to be reached, locally targeted drug-aerosol delivery is imperative. For that reason the underlying principle of a future line of "smart inhalers" is introduced. Specifically, by generating a controlled air-particle stream, most of the inhaled drug aerosols reach predetermined lung sites, which are associated with specific diseases and/or treatments. Using the same human upper airway model, experimentally confirmed computer predictions of controlled particle transport from mouth to generation 3 are provided.
INTRODUCTION P
RESSURIZED METERED DOSE INHALERS (pMDIs), dry powder inhalers and nebulizers are the most common oral drug delivery devices. The pMDI is a compact, easy-to-use droplet spray dispenser for multiple-dose treatment of pulmonary diseases, the most common being asthma. Typically 200 high-pressure (P canister Ͼ 10 atm) actuations, containing 20 to 5000 g of drug in metered volumes of 25 to 100 L, can be generated and inhaled. [1] [2] [3] A key component of the device is the actuator spray nozzle, which controls the atomization process and resultant spray formation in terms of spray angle and droplet size distribution. The formulation in pMDIs consists of a therapeutic material and a propellant as well as surfactants and other excipients which dissuade drug-aerosol coagulation and lubricate moving parts of the metering valve. While pressurized chlorofluorocarbon (CFC) substances are being phased out worldwide because released chlorine atoms deplete the earth's ozone layer, hydrofluoroalkane (e.g., HFA-134a and HFA-227) have become replacement propellants. 4, 5 However, due to the different physical and chemical properties of CFC and HFA, both the formulation in pMDIs and their structural elements had to be modified. 6 In any case, 70 to 80% of the discharged formulation of the discharged formulation is liquid with nozzle exit velocities in the range of 150 to 225 m/sec.
The overall goal for pMDIs is to deliver most of the medicine (e.g., BDP for asthma 7 ) to a patient's bronchopulmonary tree and lower airways, that is, avoiding depositions inside the actuator and in the oral airways. Numerous in vitro and in vivo tests with pMDIs have been conducted to approach that goal; however, no computational fluid-particle dynamics (CFPD) analysis has been found in the open literature. Usually companies employ a geometric model of the upper airways, that is, the United State Pharmacopoeia (USP) throat and the Andersen cascade impactor, to estimate particle size from pMDIs and to estimate deposition pattern using gamma scintigraphy (see http://www.westechinstruments.com). For example, Leach et al. 8 compared CFC-and HFA-driven pMDI performances. While most of the drug aerosols from CFC-pMDIs remained in the oropharyngeal region (i.e., 80-90%), HFA-pMDIs delivered up to 60% of the inhaled medicine into the central and intermediate lung zones. Such an increase in drug delivery with newer HFA-pMDIs can be contributed to the improved formulation characteristics and actuator design, resulting in smaller drug aerosols. In vitro tests were carried out by a number of researchers. [9] [10] [11] [12] They argued that the use of a realistic human upper airway replica is preferable to the USP throat and compared CFC-versus HFA-pMDI performances, considering the holding chamber and consistent drug dosing, the effect of temperature, the influence of spacers, and the impact of orifice diameter on spray force.
In this paper, the results for a conventional inhaler as well as the methodology for a new smart inhaler system are discussed. Specially, the airflow and microdroplet dynamics inside a pMDI model attached to a representative human upper airway replica are simulated, considering different propellants, exit-nozzle diameters, and spacer impact. The work relies on the contributions by Shi and Kleinstreuer 13 describing the dynamics of high-pressure sprays and by Kleinstreuer and Zhang 14 simulating air-particle flow in a human airway model adapted from Cheng et al. 15 The key question addressed here is how much of the inhaled medicine, that is, droplet mass fraction, travels past the trachea, and hence, reaches the bronchial tree and beyond.
While pMDIs may deliver some of the inhaled medicine to the central lung region, most treatments require high-percentage drug aerosol deposition at specific lung sites, such as tumors, or lung regions, for example, alveolated ducts. For example, Kleinstreuer and Zhang 16 analyzed a critical tumor size for maximum drug-aerosol deposition under various inhalation conditions. Some drugs are so aggressive and/or expensive that targeted aerosol delivery is imperative. Clearly, the development and testing of such a new generation of inhalers is a very active research area (refer to www.uspto.gov/patft/index.html). Some preliminary results, based on a new "controlled air-particle stream" methodology, 17 are presented (see later section). A smart inhaler system which implements the idea is discussed by Kleinstreuer and Seelecke. 18 
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drag forces on the droplets. The drag force will result in droplet deformation, as determined by the Weber number, which is generally defined as the ratio of the inertia force to surface tension:
where g is the gas density, V slip is the relative velocity (i.e., slip velocity), r is the droplet radius, and is the coefficient of liquid surface tension.
g V 2 slip r ᎏ inhalation was described by a low Reynolds number k-turbulence model. 14, 19 The spray evolution was simulated with gas-liquid interactive Enhanced Taylor Analogy Breakup (ETAB) model, 13, 20 while the resulting droplet trajectories were determined with Newton's second law governed by drag and gravity as the major forces for dispersed droplets in low density gas flow, that is,
where x → p is the particle position, u → p is the particle velocity, m p is the particle mass, g is the gas density, G → is the gravitational force, C D is the drag coefficient, and d p is the particle diameter. A justification for the use of Equation (1) is provided in Kleinstreuer, 17 among other sources. Considering spherical microdroplets at low formulation mass flow rates 1 (Ͻ0.5 g/sec), the two phases are decoupled in the present Eulerian (gas)-Lagrangian (liquid) modeling approach. 21 Furthermore, turbulent airflow effects on droplet trajectories were neglected because the focus was on aerosol transport and not deposition (see Matida et al. 22 ), as well as uniformity in operational device comparisons.
The ETAB model, a basic theory for liquid droplet breakup, was selected because of its accuracy and stability. 13, 20 Specifically, if a droplet is exposed to gas flow and there is a velocity difference (i.e., slip velocity) between droplets and surrounding gas, the gas phase will exert large Thus, the Weber number connects the gas-induced drag force, which leads to droplet deformation against liquid surface tension which tends to maintain a spherical droplet shape. Significant deformation starts at a Weber number of unity. Above a certain value of the Weber number, droplet deformation leads to breakup. The ETAB model is a Weber number-based, spray droplet breakup model to predict droplet lifetime, children droplet size, and momentum. Detailed mathematical descriptions can be found elsewhere. 13, 20 Droplet evaporation was simulated with a lumped parameter model 23 where the evaporation rate depends on the droplet diameter, gas/vapor mixture density, diffusivity, heat transfer number, and presence of surfactants. Specifically, the droplet evaporation model used in this study is based on theory reviewed by Faeth: 23
where m и d is the mass evaporation rate (kg/s), d p is the droplet diameter, ෆ is gas/vapor mixture density, D AB is the formulation vapor phase diffusivity in air, and B T is the heat transfer number defined as:
Here, c p is the formulation specific heat and T wb is the formulation wet bulb temperature. Droplets are assumed to be at their wet-bulb temperature of the propellant and remain at this temperature throughout their life history. T ref is the reference temperature which is calculated with the onethird rule of Sparrow and Gregg, 28 that is,
where T ϱ ϭ 20°C is the ambient temperature. A representative geometric model of a pMDI with an appropriate spacer (4.2-cm diameter and 10.5-cm long) was constructed and connected to a human upper airway model 14 which was adapted from Cheng et al. 15 The diameter variations along the present oral airway from mouth to trachea are almost the same as the hydraulic diameters from the human cast reported by Cheng et al. 15 Variations to the actual cast include
the circular cross sections, a short mouth inlet with a diameter of 2 cm, a modified soft palate, and a strong bend. A typical pMDI consists of a canister containing the formulation (p canister Ϸ 10 atm) which is connected to a metering valve producing dosages of 25 to 100 L. The user triggers the release of the measured formulation through the actuatornozzle, generating a liquid jet (v nozzle Յ 150 m/sec) which breaks up in two stages where secondary-breakup (ETAB model) determines droplet-spray characteristics. Air was assumed to enter through the annular space between canis- ter and inhaler body (see Fig. 1b ). The nozzle, with an orifice diameter of 0.5 mm and 0.25 mm, is located where the center lines of the canister and mouthpiece intersect. Roundoff of component edges was implemented to reflect a realistic design.
Numerical method and model validations
The numerical solutions of the governing equations for airflow, droplet formation, and droplet trajectories, subject to appropriate boundary conditions, as well as models for air turbulence and droplet evaporation, were carried out with a user-enhanced commercial finite-volume code CFX 10.0 (Ansys, Inc., Canonsburg, PA). The final mesh topology (Fig.  1a) using the mesh generator ICEM-CFD (ICEM-CFD Engineering Inc., Berkeley, CA) was determined via mesh refinement until grid independence of the solutions was achieved. A KLEINSTREUER ET AL. 300 particle number-independence test was also conducted in order to verify that 2000 particles were sufficient. Specifically, particle deposition, including deposition efficiency, was tested to be independent of the number of particles released. The flow field solutions were assumed to be converged when the dimensionless mass and momentum residual ratios were Ͻ0.0001. All computations were performed on a dual Xeon Intel 3G Dell workstation (CFPD Laboratory, Department of Mechanical and Aerospace Engineering, NC State University) as well as on an IBM Linux Cluster at NCSU's High-Performance Computing Center (Raleigh, NC). The basic boundary conditions were as follows (see Fig. 1 ):
1. Inlet: uniform velocity profile for Q ϭ 30 L/min and a turbulence intensity value of 5% for the turbulence kinetic energy. 2. Outlet: given pressure condition. 3. Walls: perfect particle absorption condition, that is, particles that touch the wall are assumed as deposited and will not be considered further. 4. Actuator nozzle: given droplet initial diameter, velocity, and spray angle (see Table 1 ).
Validation of the present computer simulation model with experimental data sets included spherical microparticle deposition in the human upper airways, that is, mouth to trachea (Fig. 2) , as well as droplet-spray evolution in terms of a mean axial velocity profile (Fig. 3a) and transient spray penetration depth for two pressure levels (Fig. 3b) .
As expected, Figure 2 shows that the particle deposition efficiency increases rapidly for 10 3 Յ IP Յ 10 4 , where the impaction parameter, IP ϭ Q и d 2 p , features two key quantities affecting microparticle deposition, that is, particle diameter and flow rate. It should be noted that the inhaler design is not included in the simulation results presented in Figure 2. Figure 3 confirms that the ETAB model used for simulating droplet formation is appropriate; specifically, at x ϭ 600 D downstream from the nozzle exit with orifice diameter D, the axial velocity profile averaged for all spray droplets matches experimental data points reasonably well. Figure 3b depicts two important aspects in the simulation of droplet spray behavior, that is, how far and how fast a spray front expands for different back pressures.
Necessary geometric, operational, and property data for both the pMDI and propellants are summarized in Table 1 .
RESULTS AND DISCUSSION
pMDI initiated air-droplet dynamics
The airflow field in terms of the mid-plane streamlines and local velocity magnitudes is shown in Figure 4 . Air is uniformly sucked in via the inlet ring at Q ϭ 30 L/min, forming several vortices inside the inhaler body and attached spacer. Due to the sudden expansion, the airflow velocity in the spacer (ID ϭ 4.2 cm) is reduced, increasing coupled droplet residence time and hence evaporation rate. Air accelerates again in the oral cavity (mouth diameter 2 cm) and becomes fully turbulent in the trachea because of the constriction in the larynx. Before leaving the trachea, the airflow has largely been relaminarized.
Considering first a CFC-pMDI for droplet transport and deposition, Figures 5 and 6 depict the simulation results without a spacer and with a spacer, respectively. For CFC-driven inhalers, the exit nozzle diameter, which greatly influences the droplet formation process and resulting spray characteristics, is typically 0.5 mm. As depicted in Figure 5a , the dense spray cone distributes droplets almost fully in the oral cavity where most the droplets deposit, that is, about 90% (Fig. 5b) . As a result, only a minor portion travels down the trachea (Fig. 5a) , leading potentially to a drug deposition in the lung of about 5% (Fig. 5b) . Attaching a spacer ( Fig. 6a and b) improves the situation measurably. First of all, the extra tube reduces both the droplet spray speed and average droplet size significantly; hence, it allows for broader droplet dispersion in the human upper airways (Fig. 6a) . Although almost 40% of the released droplets deposit in the spacer, over 50% make it into the lung regions. Experimental data also shows that by adding spacers, the deposition in the oral airways can be reduced significantly. 9, 10 Switching to HFA as a propellant in a pMDI with d nozzle ϭ 0.25 mm improves the potential of drug aerosol reaching the lung dramatically without or with a spacer (Figs. 7 and 8) . Specifically, because of better atomization achieved by using HFA and a smaller nozzle orifice, the smaller droplets are better dispersed throughout the airways (Fig. 7a) , and as a result, oral airway deposition (53.4%) is almost balanced by the throughput (46.6%) for a pMDI without a spacer (Fig. 7b) . When a spacer is attached, hardly any droplets touch the tube wall ( Fig. 8a and b) because the 0.25-mm nozzle opening generates more confined spray characteristics. As a result, almost 75% of the released droplets travel to the lung.
The present simulation results are in agreement with both in vitro and in vivo tests (Fig. 9) . Clearly, HFA-pMDIs perform much better than CFC-pMDIs, that is, oral airway depositions are 40-60% (HFA) versus 89-90% (CFC). Any discrepancies between experimental and theoretical results may stem from three major factors:
• Droplet coalescence was not included in the present model, that is, the axial mean droplet velocities may be underestimated due to a lower particle inertia effect.
• Assumed pMDI spray conditions, for example, droplet velocity at nozzle exit, spray angle, and liquid mass flow rate, may deviate from actual (experimental) conditions. • Use of models, for example, ETAB, which do not fully match actual liquid-particle dynamics processes.
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FIG. 9.
Comparison between the simulated and measured pMDI droplet deposition fractions. deposition efficiency increases from 5.2% (Fig. 5b) to 23.2% (Table 2) ; but, it is still half of that for comparable HFA-pMDI (Fig. 7b and Table 2 ). Clearly, HFA properties such as its lower surface tension and boiling point (Table 1 ) help in producing smaller droplets.
Smart inhaler air-particle dynamics
While HFA-pMDIs with spacers may cause up to 75% of released drug aerosols to pass through the trachea (Fig. 8b) , their subsequent transport and deposition are arbitrary, that is, pMDIs as most all inhalers are nondirectional. This is not of great concern when routine asthma treatment is required, because the drug is inexpensive and usually no systemic side effects occur. Multiple pMDI actuations should ultimately supply sufficient medicine to the inflamed airways, if they are located in the upper bronchial tree.
However, in cases where expensive and/or aggressive drug aerosols have to reach a specific point in the lung (e.g., to coat a tumor) or a specific lung region (e.g., to achieve rapid drug absorption of, say, insulin), targeted drug-aerosol delivery would be most desirable. This can be a achieved with a new "controlled air-particle stream" methodology. Predetermined lung sites, associated with a specific disease or treatment, can be targeted with an appropriate inhaled air stream with suitable drug-aerosol characteristics, in terms of density and size, as well as release position. 16, 17 The necessary device to generate such controlled air-particle streams is being patented by NCSU.
As an example, an upper airway model consisting of the oral airway model and a symmetric, triple-bifurcation lung airway model representing generations G0 (trachea) to G3 (see Fig.  10 ), was employed to investigate the transport of inhaled drug aerosols. The detailed description of this upper airway model can be found in Zhang et al. 29 The velocity field and particle distributions in the trachea of the oral airway model were adjusted as the inlet conditions of the bifurcating airway segment (i.e., Generations G0 to G3). 19, 29 The air flow and microparticle transport were simulated with a commercial finitevolume code CFX4 (Ansys, Inc.) and our inhouse off-line F90 particle trajectory code. 29 The computations were conducted on an IBM p575 machine with multiple POWER5 processors. The accurate prediction of the conditions for a controlled air-particle stream is a prerequisite for designing any "smart inhaler system." As a first A B step, the simulated particle distributions in the oral airway model with different inlet release positions were compared with experimental visualizations (see Fig. 11 ), assuming a steady inspiratory flow rate of 8 L/min and a spherical particle diameter of 7 m. One thousand particles were released at the oral inlet. The experimental measurements, a proof of concept, were conducted in-house using LDV (Laser Doppler Velocimetry) technique. Clearly, the simulated particle distributions agree well with the experimental visualizations. Minor discrepancies may be attributed to: (1) slight differences in inlet release positions between the simulations and experiments; (2) differences in visualization locations; (3) differences in the geometries (e.g., there was a transition tube in the experimental setup and the airway geometry becomes slightly different after manufacturing); and (4) the difference in air humidity, particle size, and flow rate, that is, particle distributions are sensitive to factors (1) and (2). The specific inlet positions of aerosols which land on different targeted sites are determined via ''backtracking,'' and then release-controlled air-particle streams are generated so that most aerosols deposit in the desired lung regions, for example, inflamed left or right lower airways, etc. Specifically, depositions of 7 m particles (a representative size of drug aerosols) with a relatively low inhalation flow rate (i.e., 8 L/min) are minor in the upper airways due to negligible inertial impaction (DF oral ϭ 1.47%, and DF G0-3 ϭ 0.76%). Thus, most of them can enter the deeper lung regions. In general, particles released from the left and right sides of the circular mouth entrance enter the left and right lungs, respectively. However, the inlet positions of particles leaving different portions of G3 vary irregularly due to the effects of secondary flows. The feasibility of an inhaler based on the new drug-aerosol targeting methodology may be enhanced if the particles can be released from orbit points with one or more critical radii. In this case, a tube-aligned nozzle with adjustable particleoutlet diameter can rotate on a predetermined orbital path. For example, the targeted regions for release positions 1 to 4 shown in Figure 12 are located in the lower airways after generation G3 (see Fig. 13 and Table 3 respectively, while they transport into side and central portions of the right lung after exiting from G35 and G38 (see Fig. 10 ). As summarized in Table 3 , with the controlled inlets the capture efficiency of particles in the targeted areas can increase from about 10% to 60-100%. Distributions of particles entering targeted (outlet) airways are depicted in Figure 13 . Some particle dispersion occurs for Inlet positions 2 to 4 because of the influence of secondary flows and lack of humidity. In contrast, inlet position 1 happens to be located in a larger particle release area reaching the G31 airway outlet. In any case, dispersion could be greatly avoided when using drug aerosols with mildly attractive surface properties via surfactant coating. Furthermore, the relatively high humidity environment in lung airways should reduce microparticle dispersion. Clearly, the development of smart inhalers based on the new methodology may encounter several challenges, such as intersubject variability, device robustness, and nonuniform drugaerosol characteristics. 
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